Literature DB >> 9836606

Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.

R M Jones1, S A Hjorth, T W Schwartz, P S Portoghese.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9836606     DOI： 10.1021/jm9805182

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  25 in total

Review 1.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 2.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

Review 3.  Molecular recognition of opioid receptor ligands.

Authors:  Brian E Kane; Bengt Svensson; David M Ferguson
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

Review 4.  Kappa-opioid ligands in the study and treatment of mood disorders.

Authors:  William A Carlezon; Cécile Béguin; Allison T Knoll; Bruce M Cohen
Journal:  Pharmacol Ther       Date:  2009-06-02       Impact factor: 12.310

5.  14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.

Authors:  Guo Li; Lindsey C K Aschenbach; Hengjun He; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-12-29       Impact factor: 2.823

6.  N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.

Authors:  F Ivy Carroll; Sachin Chaudhari; James B Thomas; S Wayne Mascarella; Kenneth M Gigstad; Jeffrey Deschamps; Hernán A Navarro
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

Review 7.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

8.  Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy.

Authors:  Kevin J Frankowski; Michael P Hedrick; Palak Gosalia; Kelin Li; Shenghua Shi; David Whipple; Partha Ghosh; Thomas E Prisinzano; Frank J Schoenen; Ying Su; S Vasile; Eduard Sergienko; Wilson Gray; Santosh Hariharan; Loribelle Milan; Susanne Heynen-Genel; Arianna Mangravita-Novo; Michael Vicchiarelli; Layton H Smith; John M Streicher; Marc G Caron; Lawrence S Barak; Laura M Bohn; Thomas D Y Chung; Jeffrey Aubé
Journal:  ACS Chem Neurosci       Date:  2012-01-20       Impact factor: 4.418

9.  K303⁶·⁵⁸ in the μ opioid (MOP) receptor is important in conferring selectivity for covalent binding of β-funaltrexamine (β-FNA).

Authors:  Kelly M DiMattio; Chongguang Chen; Lei Shi; Lee-Yuan Liu-Chen
Journal:  Eur J Pharmacol       Date:  2014-12-04       Impact factor: 4.432

10.  Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).

Authors:  Juan Pablo Cueva; Tingwei Bill Cai; S Wayne Mascarella; James B Thomas; Hernán A Navarro; F Ivy Carroll
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.